A specific question in a small group

Gregorič and colleagues studied 25 men with obesity, type 2 diabetes and functional hypogonadism. Their randomized, open-label study compared semaglutide with testosterone replacement over 24 weeks. It assessed semen characteristics and hormonal and symptom measures, rather than asking whether a broad population should use a peptide for fertility.

In the semaglutide group, the reported median proportion of morphologically normal sperm increased from 2% to 4%. Sperm concentration and total number fell in the testosterone group. These findings make the comparator important: a difference between two treatments is not automatically evidence of benefit compared with no treatment.

Read the endpoint before the headline

Morphology describes appearance under the study’s laboratory assessment. It is not the same endpoint as conception or a live birth. With a small sample and a narrow clinical population, this paper is a starting point for further investigation, not a universal statement about men’s reproductive health. Open-label design also matters when interpreting participant-reported symptoms.

S7’s reading rule is to write down three separate questions: what was measured, who was studied, and what remains unknown? A statistically notable measurement should not silently become a promise about an outcome the reader actually cares about. Larger, appropriately controlled research would need to address that gap directly.

Clinical evidence is not a vendor-vial endorsement

FDA distinguishes approved medicines from unapproved semaglutide products, which have not undergone the same review for safety, effectiveness and quality. A catalog ingredient name does not establish equivalence to the product used in a clinical study. This article is an educational interpretation of published research, not medical advice, a fertility recommendation or instructions for using any product.